| Literature DB >> 25446020 |
Amr El-Husseini1, Schot Hannan2, Ahmed Awad2, Stuart Jennings2, Virgilius Cornea3, B Peter Sawaya2.
Abstract
Thrombotic microangiopathy (TMA) is a severe disorder with poor outcomes. The cause is unknown for many patients, although TMA is associated with connective tissue disorders, including systemic lupus erythematosus (SLE). While uncommon, TMA is one of the most serious complications of SLE and in many cases may be resistant to therapy. We report a patient with SLE complicated by TMA that was refractory to standard therapy but responded well to eculizumab, with continued remission after 1 year of follow-up. Eculizumab might be useful in the management of resistant cases of TMA caused by SLE.Entities:
Keywords: Thrombotic microangiopathy (TMA); acute kidney injury (AKI); atypical hemolytic uremic syndrome (aHUS); eculizumab; kidney biopsy; lupus nephritis; proteinuria; systemic lupus erythematosus (SLE)
Mesh：
Substances：
Year: 2014 PMID： 25446020 DOI： 10.1053/j.ajkd.2014.07.031
Source DB: PubMed Journal: Am J Kidney Dis ISSN： 0272-6386 Impact factor: 8.860